Literature DB >> 27515591

High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans.

Benjamin Bowe1, Yan Xie1, Hong Xian1,2, Sumitra Balasubramanian1, Mohamed A Zayed1,3,4, Ziyad Al-Aly5,6,7.   

Abstract

BACKGROUND AND OBJECTIVES: The relationship between HDL cholesterol and all-cause mortality in patients with kidney disease is not clear. We sought to characterize the relationship of HDL cholesterol and risk of death and examine the association by eGFR levels. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We built a cohort of 1,764,986 men who were United States veterans with at least one eGFR between October of 2003 and September of 2004 and followed them until September of 2013 or death.
RESULTS: Patients with low HDL cholesterol and low eGFR had a higher burden of comorbid illnesses. Over a median of 9.1 years (interquartile range, 7.7-9.4 years), 26,247 (40.1%), 109,222 (32.3%), 152,625 (29.2%), 113,785 (28.5%), and 139,803 (31.8%) participants with HDL cholesterol ≤25, >25 to <34, ≥34 to ≤42, >42 to <50, and ≥50 mg/dl died. In adjusted survival models, compared with the referent group of patients with low HDL cholesterol (≤25 mg/dl), intermediate HDL cholesterol levels (>25 to <34, ≥34 to ≤42, and >42 to <50 mg/dl) were associated with lower risk of death across all levels of eGFR. The lower risk was partially abrogated in those with high HDL cholesterol (≥50 mg/dl), and the risk of death was similar to the referent category among those with eGFR<30 or ≥90 ml/min per 1.73 m2. Analysis by HDL cholesterol deciles and spline analyses suggest that the relationship between HDL cholesterol and death follows a U-shaped curve. There was a significant interaction between eGFR and HDL cholesterol in that lower eGFR attenuated the salutary association of HDL cholesterol and risk of death (P for interaction <0.01). Presence of coronary artery disease attenuated the lower risk of high HDL cholesterol and all-cause mortality in those with eGFR≥60 ml/min per 1.73 m2 (P for interaction <0.05).
CONCLUSIONS: Our results show a U-shaped relationship between HDL cholesterol and risk of all-cause mortality across all eGFR categories. The risk is modified by eGFR and cardiovascular disease.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  Cardiovascular Diseases; Cholesterol, HDL; Epidemiology and outcomes; Humans; United States; Veterans; chronic kidney disease; coronary artery disease; hypercholesterolemia; lipids; mortality; mortality risk

Mesh:

Substances:

Year:  2016        PMID: 27515591      PMCID: PMC5053782          DOI: 10.2215/CJN.00730116

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  28 in total

1.  A formula to estimate the approximate surface area if height and weight be known. 1916.

Authors:  D Du Bois; E F Du Bois
Journal:  Nutrition       Date:  1989 Sep-Oct       Impact factor: 4.008

2.  HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction.

Authors:  Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

3.  Dysfunctional high-density lipoprotein in patients on chronic hemodialysis.

Authors:  Suguru Yamamoto; Patricia G Yancey; T Alp Ikizler; W Gray Jerome; Ryohei Kaseda; Brian Cox; Aihua Bian; Ayumi Shintani; Agnes B Fogo; Macrae F Linton; Sergio Fazio; Valentina Kon
Journal:  J Am Coll Cardiol       Date:  2012-11-07       Impact factor: 24.094

4.  Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.

Authors:  Yan Xie; Benjamin Bowe; Tingting Li; Hong Xian; Sumitra Balasubramanian; Ziyad Al-Aly
Journal:  J Am Soc Nephrol       Date:  2016-04-14       Impact factor: 10.121

Review 5.  HDL metabolism and activity in chronic kidney disease.

Authors:  Nosratola D Vaziri; Mohamad Navab; Alan M Fogelman
Journal:  Nat Rev Nephrol       Date:  2010-03-23       Impact factor: 28.314

6.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

7.  Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality.

Authors:  Yan Xie; Benjamin Bowe; Hong Xian; Sumitra Balasubramanian; Ziyad Al-Aly
Journal:  Am J Kidney Dis       Date:  2016-03-04       Impact factor: 8.860

8.  Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial.

Authors:  Roberto S Kalil; Jeffrey H Wang; Ian H de Boer; Roy O Mathew; Joachim H Ix; Arif Asif; Xuefeng Shi; William E Boden
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

9.  Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death.

Authors:  Yan Xie; Benjamin Bowe; Hong Xian; Sumitra Balasubramanian; Ziyad Al-Aly
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

10.  Association of high-density lipoprotein cholesterol with the estimated glomerular filtration rate in a community-based population.

Authors:  Fan Wang; Jin Zheng; Ping Ye; Leiming Luo; Yongyi Bai; Ruyi Xu; Li Sheng; Tiehui Xiao; Hongmei Wu
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

View more
  61 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

Review 2.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

3.  High density lipoproteins and kidney function: the friend turned foe?

Authors:  Lina Badimon; Gemma Vilahur; Judit Cubedo
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  High-density lipoprotein: quantity or quality?

Authors:  Konstantinos Tziomalos
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

5.  High density lipoprotein cholesterol and risk of death.

Authors:  Ziyad Al-Aly
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

6.  Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients.

Authors:  Yasunori Suematsu; Masaki Goto; Christina Park; Ane C F Nunes; WangHui Jing; Elani Streja; Connie M Rhee; Siobanth Cruz; Moti L Kashyap; Nosratola D Vaziri; Vasanthy Narayanaswami; Kamyar Kalantar-Zadeh; Hamid Moradi
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

7.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

8.  Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD.

Authors:  Benjamin Bowe; Yan Xie; Hong Xian; Tingting Li; Ziyad Al-Aly
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-27       Impact factor: 8.237

Review 9.  Liver Sinusoidal Endothelial Cell: An Update.

Authors:  Laurie D DeLeve; Ana C Maretti-Mira
Journal:  Semin Liver Dis       Date:  2017-12-22       Impact factor: 6.115

10.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.